Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients : a Phase II, Historical Control, Biomarker-selected Study
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Sintilimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Nov 2020 New trial record